Reviews Proleukin


No reviews yet.

Proleukin Drug Description
PROLEUKIN®
(aldesleukin) For Injection

WARNINGS
Therapy with PROLEUKIN® (aldesleukin) for injection should be restricted
to patients with normal cardiac and pulmonary functions as defined by thallium stress testing and formal pulmonary function testing. Extreme caution should
be used in patients with a normal thallium stress test and a normal pulmonary
function test who have a history of cardiac or pulmonary disease.
PROLEUKIN should be administered in a hospital setting under the supervision
of a qualified physician experienced in the use of anticancer agents. An intensive
care facility and specialists skilled in cardiopulmonary or intensive care medicine
must be available.
PROLEUKIN administration has been associated with capillary leak syndrome
(CLS) which is characterized by a loss of vascular tone and extravasation of
plasma proteins and fluid into the extravascular space. CLS results in hypotension
and reduced organ perfusion which may be severe and can result in death. CLS
may be associated with cardiac arrhythmias (supraventricular and ventricular),
angina, myocardial infarction, respiratory insufficiency requiring intubation,
gastrointestinal bleeding or infarction, renal insufficiency, edema, and mental
status changes.
PROLEUKIN treatment is associated with impaired neutrophil function (reduced
chemotaxis) and with an increased risk of disseminated infection, including
sepsis and bacterial endocarditis. Consequently, preexisting bacterial infections
should be adequately treated prior to initiation of PROLEUKIN therapy. Patients
with indwelling central lines are particularly at risk for infection with gram
positive microorganisms. Antibiotic prophylaxis with oxacillin, nafcillin, ciprofloxacin,
or vancomycin has been associated with a reduced incidence of staphylococcal
infections.
PROLEUKIN administration should be withheld in patients developing moderate
to severe lethargy or somnolence; continued administration may result in coma.

DRUG DESCRIPTION



What are the possible side effects of aldesleukin (Proleukin)?

If you experience any of the following serious side effects from aldesleukin, contact your doctor immediately:

an allergic reaction (including difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
decreased bone marrow function or blood problems (extreme fatigue; easy bruising or bleeding; black, bloody or tarry stools; or fever, chills, or infection);
capillary leak syndrome (leaking of blood plasma and fluid from the blood vessels),...
Read All Potential Side Effects for Proleukin »




PROLEUKIN® (aldesleukin) for injection, a human recombinant interleukin-2
product, is a highly purified protein with a molecular weight of approximately
15,300 daltons. The chemical name is des-alanyl-1, serine-125 human interleukin-2.
PROLEUKIN, a lymphokine, is produced by recombinant DNA technology using a genetically
engineered E. colistrain containing an analog of the human interleukin-2
gene. Genetic engineering techniques were used to modify the human IL-2 gene,
and the resulting expression clone encodes a modified human interleukin-2. This
recombinant form differs from native interleukin-2 in the following ways: a)
PROLEUKIN is not glycosylated because it is derived from E. coli ; b)
the molecule has no N-terminal alanine; the codon for this amino acid was deleted
during the genetic engineering procedure; c) the molecule has serine substituted
for cysteine at amino acid position 125; this was accomplished by site specific
manipulation during the genetic engineering procedure; and d) the aggregation
state of PROLEUKIN is likely to be different from that of native interleukin-2.
The in vitro biological activities of the native nonrecombinant molecule
have been reproduced with PROLEUKIN.1,2
PROLEUKIN is supplied as a sterile, white to off-white, lyophilized cake in single-use vials intended for intravenous (IV) administration. When reconstituted with 1.2 mL Sterile Water for Injection, USP, each mL contains 18 million IU (1.1 mg) PROLEUKIN, 50 mg mannitol, and 0.18 mg sodium dodecyl sulfate, buffered with approximately 0.17 mg monobasic and 0.89 mg dibasic sodium phosphate to a pH of 7.5 (range 7.2 to 7.8). The manufacturing process for PROLEUKIN involves fermentation in a defined medium containing tetracycline hydrochloride. The presence of the antibiotic is not detectable in the final product. PROLEUKIN contains no preservatives in the final product.
PROLEUKIN biological potency is determined by a lymphocyte proliferation bioassay
and is expressed in International Units (IU) as established by the World Health
Organization 1st International Standard for Interleukin-2 (human). The relationship
between potency and protein mass is as follows:
18 million (18 x 106) IU PROLEUKIN = 1.1 mg protein
REFERENCES
1. Doyle MV, Lee MT, Fong S. Comparison of the biological activities of human
recombinant interleukin-2125 and native interleukin-2. J Biol
Response Mod 1985; 4:96-109.
2. Ralph P, Nakoinz I, Doyle M, et al. Human B and T lymphocyte stimulating
properties of interleukin-2 (IL-2) muteins. In: Immune Regulation By Characterized
Polypeptides. Alan R. Liss, Inc. 1987; 453-62.Last reviewed on RxList: 9/11/2008




Proleukin Drug Description
PROLEUKIN®
(aldesleukin) For Injection

WARNINGS
Therapy with PROLEUKIN® (aldesleukin) for injection should be restricted
to patients with normal cardiac and pulmonary functions as defined by thallium stress testing and formal pulmonary function testing. Extreme caution should
be used in patients with a normal thallium stress test and a normal pulmonary
function test who have a history of cardiac or pulmonary disease.
PROLEUKIN should be administered in a hospital setting under the supervision
of a qualified physician experienced in the use of anticancer agents. An intensive
care facility and specialists skilled in cardiopulmonary or intensive care medicine
must be available.
PROLEUKIN administration has been associated with capillary leak syndrome
(CLS) which is characterized by a loss of vascular tone and extravasation of
plasma proteins and fluid into the extravascular space. CLS results in hypotension
and reduced organ perfusion which may be severe and can result in death. CLS
may be associated with cardiac arrhythmias (supraventricular and ventricular),
angina, myocardial infarction, respiratory insufficiency requiring intubation,
gastrointestinal bleeding or infarction, renal insufficiency, edema, and mental
status changes.
PROLEUKIN treatment is associated with impaired neutrophil function (reduced
chemotaxis) and with an increased risk of disseminated infection, including
sepsis and bacterial endocarditis. Consequently, preexisting bacterial infections
should be adequately treated prior to initiation of PROLEUKIN therapy. Patients
with indwelling central lines are particularly at risk for infection with gram
positive microorganisms. Antibiotic prophylaxis with oxacillin, nafcillin, ciprofloxacin,
or vancomycin has been associated with a reduced incidence of staphylococcal
infections.
PROLEUKIN administration should be withheld in patients developing moderate
to severe lethargy or somnolence; continued administration may result in coma.

DRUG DESCRIPTION



What are the possible side effects of aldesleukin (Proleukin)?

If you experience any of the following serious side effects from aldesleukin, contact your doctor immediately:

an allergic reaction (including difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
decreased bone marrow function or blood problems (extreme fatigue; easy bruising or bleeding; black, bloody or tarry stools; or fever, chills, or infection);
capillary leak syndrome (leaking of blood plasma and fluid from the blood vessels),...
Read All Potential Side Effects for Proleukin »




PROLEUKIN® (aldesleukin) for injection, a human recombinant interleukin-2
product, is a highly purified protein with a molecular weight of approximately
15,300 daltons. The chemical name is des-alanyl-1, serine-125 human interleukin-2.
PROLEUKIN, a lymphokine, is produced by recombinant DNA technology using a genetically
engineered E. colistrain containing an analog of the human interleukin-2
gene. Genetic engineering techniques were used to modify the human IL-2 gene,
and the resulting expression clone encodes a modified human interleukin-2. This
recombinant form differs from native interleukin-2 in the following ways: a)
PROLEUKIN is not glycosylated because it is derived from E. coli ; b)
the molecule has no N-terminal alanine; the codon for this amino acid was deleted
during the genetic engineering procedure; c) the molecule has serine substituted
for cysteine at amino acid position 125; this was accomplished by site specific
manipulation during the genetic engineering procedure; and d) the aggregation
state of PROLEUKIN is likely to be different from that of native interleukin-2.
The in vitro biological activities of the native nonrecombinant molecule
have been reproduced with PROLEUKIN.1,2
PROLEUKIN is supplied as a sterile, white to off-white, lyophilized cake in single-use vials intended for intravenous (IV) administration. When reconstituted with 1.2 mL Sterile Water for Injection, USP, each mL contains 18 million IU (1.1 mg) PROLEUKIN, 50 mg mannitol, and 0.18 mg sodium dodecyl sulfate, buffered with approximately 0.17 mg monobasic and 0.89 mg dibasic sodium phosphate to a pH of 7.5 (range 7.2 to 7.8). The manufacturing process for PROLEUKIN involves fermentation in a defined medium containing tetracycline hydrochloride. The presence of the antibiotic is not detectable in the final product. PROLEUKIN contains no preservatives in the final product.
PROLEUKIN biological potency is determined by a lymphocyte proliferation bioassay
and is expressed in International Units (IU) as established by the World Health
Organization 1st International Standard for Interleukin-2 (human). The relationship
between potency and protein mass is as follows:
18 million (18 x 106) IU PROLEUKIN = 1.1 mg protein
REFERENCES
1. Doyle MV, Lee MT, Fong S. Comparison of the biological activities of human
recombinant interleukin-2125 and native interleukin-2. J Biol
Response Mod 1985; 4:96-109.
2. Ralph P, Nakoinz I, Doyle M, et al. Human B and T lymphocyte stimulating
properties of interleukin-2 (IL-2) muteins. In: Immune Regulation By Characterized
Polypeptides. Alan R. Liss, Inc. 1987; 453-62.Last reviewed on RxList: 9/11/2008




Proleukin Drug Description
PROLEUKIN®
(aldesleukin) For Injection

WARNINGS
Therapy with PROLEUKIN® (aldesleukin) for injection should be restricted
to patients with normal cardiac and pulmonary functions as defined by thallium stress testing and formal pulmonary function testing. Extreme caution should
be used in patients with a normal thallium stress test and a normal pulmonary
function test who have a history of cardiac or pulmonary disease.
PROLEUKIN should be administered in a hospital setting under the supervision
of a qualified physician experienced in the use of anticancer agents. An intensive
care facility and specialists skilled in cardiopulmonary or intensive care medicine
must be available.
PROLEUKIN administration has been associated with capillary leak syndrome
(CLS) which is characterized by a loss of vascular tone and extravasation of
plasma proteins and fluid into the extravascular space. CLS results in hypotension
and reduced organ perfusion which may be severe and can result in death. CLS
may be associated with cardiac arrhythmias (supraventricular and ventricular),
angina, myocardial infarction, respiratory insufficiency requiring intubation,
gastrointestinal bleeding or infarction, renal insufficiency, edema, and mental
status changes.
PROLEUKIN treatment is associated with impaired neutrophil function (reduced
chemotaxis) and with an increased risk of disseminated infection, including
sepsis and bacterial endocarditis. Consequently, preexisting bacterial infections
should be adequately treated prior to initiation of PROLEUKIN therapy. Patients
with indwelling central lines are particularly at risk for infection with gram
positive microorganisms. Antibiotic prophylaxis with oxacillin, nafcillin, ciprofloxacin,
or vancomycin has been associated with a reduced incidence of staphylococcal
infections.
PROLEUKIN administration should be withheld in patients developing moderate
to severe lethargy or somnolence; continued administration may result in coma.

DRUG DESCRIPTION



What are the possible side effects of aldesleukin (Proleukin)?

If you experience any of the following serious side effects from aldesleukin, contact your doctor immediately:

an allergic reaction (including difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
decreased bone marrow function or blood problems (extreme fatigue; easy bruising or bleeding; black, bloody or tarry stools; or fever, chills, or infection);
capillary leak syndrome (leaking of blood plasma and fluid from the blood vessels),...
Read All Potential Side Effects for Proleukin »




PROLEUKIN® (aldesleukin) for injection, a human recombinant interleukin-2
product, is a highly purified protein with a molecular weight of approximately
15,300 daltons. The chemical name is des-alanyl-1, serine-125 human interleukin-2.
PROLEUKIN, a lymphokine, is produced by recombinant DNA technology using a genetically
engineered E. colistrain containing an analog of the human interleukin-2
gene. Genetic engineering techniques were used to modify the human IL-2 gene,
and the resulting expression clone encodes a modified human interleukin-2. This
recombinant form differs from native interleukin-2 in the following ways: a)
PROLEUKIN is not glycosylated because it is derived from E. coli ; b)
the molecule has no N-terminal alanine; the codon for this amino acid was deleted
during the genetic engineering procedure; c) the molecule has serine substituted
for cysteine at amino acid position 125; this was accomplished by site specific
manipulation during the genetic engineering procedure; and d) the aggregation
state of PROLEUKIN is likely to be different from that of native interleukin-2.
The in vitro biological activities of the native nonrecombinant molecule
have been reproduced with PROLEUKIN.1,2
PROLEUKIN is supplied as a sterile, white to off-white, lyophilized cake in single-use vials intended for intravenous (IV) administration. When reconstituted with 1.2 mL Sterile Water for Injection, USP, each mL contains 18 million IU (1.1 mg) PROLEUKIN, 50 mg mannitol, and 0.18 mg sodium dodecyl sulfate, buffered with approximately 0.17 mg monobasic and 0.89 mg dibasic sodium phosphate to a pH of 7.5 (range 7.2 to 7.8). The manufacturing process for PROLEUKIN involves fermentation in a defined medium containing tetracycline hydrochloride. The presence of the antibiotic is not detectable in the final product. PROLEUKIN contains no preservatives in the final product.
PROLEUKIN biological potency is determined by a lymphocyte proliferation bioassay
and is expressed in International Units (IU) as established by the World Health
Organization 1st International Standard for Interleukin-2 (human). The relationship
between potency and protein mass is as follows:
18 million (18 x 106) IU PROLEUKIN = 1.1 mg protein
REFERENCES
1. Doyle MV, Lee MT, Fong S. Comparison of the biological activities of human
recombinant interleukin-2125 and native interleukin-2. J Biol
Response Mod 1985; 4:96-109.
2. Ralph P, Nakoinz I, Doyle M, et al. Human B and T lymphocyte stimulating
properties of interleukin-2 (IL-2) muteins. In: Immune Regulation By Characterized
Polypeptides. Alan R. Liss, Inc. 1987; 453-62.Last reviewed on RxList: 9/11/2008




Proleukin Drug Description
PROLEUKIN®
(aldesleukin) For Injection

WARNINGS
Therapy with PROLEUKIN® (aldesleukin) for injection should be restricted
to patients with normal cardiac and pulmonary functions as defined by thallium stress testing and formal pulmonary function testing. Extreme caution should
be used in patients with a normal thallium stress test and a normal pulmonary
function test who have a history of cardiac or pulmonary disease.
PROLEUKIN should be administered in a hospital setting under the supervision
of a qualified physician experienced in the use of anticancer agents. An intensive
care facility and specialists skilled in cardiopulmonary or intensive care medicine
must be available.
PROLEUKIN administration has been associated with capillary leak syndrome
(CLS) which is characterized by a loss of vascular tone and extravasation of
plasma proteins and fluid into the extravascular space. CLS results in hypotension
and reduced organ perfusion which may be severe and can result in death. CLS
may be associated with cardiac arrhythmias (supraventricular and ventricular),
angina, myocardial infarction, respiratory insufficiency requiring intubation,
gastrointestinal bleeding or infarction, renal insufficiency, edema, and mental
status changes.
PROLEUKIN treatment is associated with impaired neutrophil function (reduced
chemotaxis) and with an increased risk of disseminated infection, including
sepsis and bacterial endocarditis. Consequently, preexisting bacterial infections
should be adequately treated prior to initiation of PROLEUKIN therapy. Patients
with indwelling central lines are particularly at risk for infection with gram
positive microorganisms. Antibiotic prophylaxis with oxacillin, nafcillin, ciprofloxacin,
or vancomycin has been associated with a reduced incidence of staphylococcal
infections.
PROLEUKIN administration should be withheld in patients developing moderate
to severe lethargy or somnolence; continued administration may result in coma.

DRUG DESCRIPTION



What are the possible side effects of aldesleukin (Proleukin)?

If you experience any of the following serious side effects from aldesleukin, contact your doctor immediately:

an allergic reaction (including difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
decreased bone marrow function or blood problems (extreme fatigue; easy bruising or bleeding; black, bloody or tarry stools; or fever, chills, or infection);
capillary leak syndrome (leaking of blood plasma and fluid from the blood vessels),...
Read All Potential Side Effects for Proleukin »




PROLEUKIN® (aldesleukin) for injection, a human recombinant interleukin-2
product, is a highly purified protein with a molecular weight of approximately
15,300 daltons. The chemical name is des-alanyl-1, serine-125 human interleukin-2.
PROLEUKIN, a lymphokine, is produced by recombinant DNA technology using a genetically
engineered E. colistrain containing an analog of the human interleukin-2
gene. Genetic engineering techniques were used to modify the human IL-2 gene,
and the resulting expression clone encodes a modified human interleukin-2. This
recombinant form differs from native interleukin-2 in the following ways: a)
PROLEUKIN is not glycosylated because it is derived from E. coli ; b)
the molecule has no N-terminal alanine; the codon for this amino acid was deleted
during the genetic engineering procedure; c) the molecule has serine substituted
for cysteine at amino acid position 125; this was accomplished by site specific
manipulation during the genetic engineering procedure; and d) the aggregation
state of PROLEUKIN is likely to be different from that of native interleukin-2.
The in vitro biological activities of the native nonrecombinant molecule
have been reproduced with PROLEUKIN.1,2
PROLEUKIN is supplied as a sterile, white to off-white, lyophilized cake in single-use vials intended for intravenous (IV) administration. When reconstituted with 1.2 mL Sterile Water for Injection, USP, each mL contains 18 million IU (1.1 mg) PROLEUKIN, 50 mg mannitol, and 0.18 mg sodium dodecyl sulfate, buffered with approximately 0.17 mg monobasic and 0.89 mg dibasic sodium phosphate to a pH of 7.5 (range 7.2 to 7.8). The manufacturing process for PROLEUKIN involves fermentation in a defined medium containing tetracycline hydrochloride. The presence of the antibiotic is not detectable in the final product. PROLEUKIN contains no preservatives in the final product.
PROLEUKIN biological potency is determined by a lymphocyte proliferation bioassay
and is expressed in International Units (IU) as established by the World Health
Organization 1st International Standard for Interleukin-2 (human). The relationship
between potency and protein mass is as follows:
18 million (18 x 106) IU PROLEUKIN = 1.1 mg protein
REFERENCES
1. Doyle MV, Lee MT, Fong S. Comparison of the biological activities of human
recombinant interleukin-2125 and native interleukin-2. J Biol
Response Mod 1985; 4:96-109.
2. Ralph P, Nakoinz I, Doyle M, et al. Human B and T lymphocyte stimulating
properties of interleukin-2 (IL-2) muteins. In: Immune Regulation By Characterized
Polypeptides. Alan R. Liss, Inc. 1987; 453-62.Last reviewed on RxList: 9/11/2008




Proleukin Drug Description
PROLEUKIN®
(aldesleukin) For Injection

WARNINGS
Therapy with PROLEUKIN® (aldesleukin) for injection should be restricted
to patients with normal cardiac and pulmonary functions as defined by thallium stress testing and formal pulmonary function testing. Extreme caution should
be used in patients with a normal thallium stress test and a normal pulmonary
function test who have a history of cardiac or pulmonary disease.
PROLEUKIN should be administered in a hospital setting under the supervision
of a qualified physician experienced in the use of anticancer agents. An intensive
care facility and specialists skilled in cardiopulmonary or intensive care medicine
must be available.
PROLEUKIN administration has been associated with capillary leak syndrome
(CLS) which is characterized by a loss of vascular tone and extravasation of
plasma proteins and fluid into the extravascular space. CLS results in hypotension
and reduced organ perfusion which may be severe and can result in death. CLS
may be associated with cardiac arrhythmias (supraventricular and ventricular),
angina, myocardial infarction, respiratory insufficiency requiring intubation,
gastrointestinal bleeding or infarction, renal insufficiency, edema, and mental
status changes.
PROLEUKIN treatment is associated with impaired neutrophil function (reduced
chemotaxis) and with an increased risk of disseminated infection, including
sepsis and bacterial endocarditis. Consequently, preexisting bacterial infections
should be adequately treated prior to initiation of PROLEUKIN therapy. Patients
with indwelling central lines are particularly at risk for infection with gram
positive microorganisms. Antibiotic prophylaxis with oxacillin, nafcillin, ciprofloxacin,
or vancomycin has been associated with a reduced incidence of staphylococcal
infections.
PROLEUKIN administration should be withheld in patients developing moderate
to severe lethargy or somnolence; continued administration may result in coma.

DRUG DESCRIPTION



What are the possible side effects of aldesleukin (Proleukin)?

If you experience any of the following serious side effects from aldesleukin, contact your doctor immediately:

an allergic reaction (including difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
decreased bone marrow function or blood problems (extreme fatigue; easy bruising or bleeding; black, bloody or tarry stools; or fever, chills, or infection);
capillary leak syndrome (leaking of blood plasma and fluid from the blood vessels),...
Read All Potential Side Effects for Proleukin »




PROLEUKIN® (aldesleukin) for injection, a human recombinant interleukin-2
product, is a highly purified protein with a molecular weight of approximately
15,300 daltons. The chemical name is des-alanyl-1, serine-125 human interleukin-2.
PROLEUKIN, a lymphokine, is produced by recombinant DNA technology using a genetically
engineered E. colistrain containing an analog of the human interleukin-2
gene. Genetic engineering techniques were used to modify the human IL-2 gene,
and the resulting expression clone encodes a modified human interleukin-2. This
recombinant form differs from native interleukin-2 in the following ways: a)
PROLEUKIN is not glycosylated because it is derived from E. coli ; b)
the molecule has no N-terminal alanine; the codon for this amino acid was deleted
during the genetic engineering procedure; c) the molecule has serine substituted
for cysteine at amino acid position 125; this was accomplished by site specific
manipulation during the genetic engineering procedure; and d) the aggregation
state of PROLEUKIN is likely to be different from that of native interleukin-2.
The in vitro biological activities of the native nonrecombinant molecule
have been reproduced with PROLEUKIN.1,2
PROLEUKIN is supplied as a sterile, white to off-white, lyophilized cake in single-use vials intended for intravenous (IV) administration. When reconstituted with 1.2 mL Sterile Water for Injection, USP, each mL contains 18 million IU (1.1 mg) PROLEUKIN, 50 mg mannitol, and 0.18 mg sodium dodecyl sulfate, buffered with approximately 0.17 mg monobasic and 0.89 mg dibasic sodium phosphate to a pH of 7.5 (range 7.2 to 7.8). The manufacturing process for PROLEUKIN involves fermentation in a defined medium containing tetracycline hydrochloride. The presence of the antibiotic is not detectable in the final product. PROLEUKIN contains no preservatives in the final product.
PROLEUKIN biological potency is determined by a lymphocyte proliferation bioassay
and is expressed in International Units (IU) as established by the World Health
Organization 1st International Standard for Interleukin-2 (human). The relationship
between potency and protein mass is as follows:
18 million (18 x 106) IU PROLEUKIN = 1.1 mg protein
REFERENCES
1. Doyle MV, Lee MT, Fong S. Comparison of the biological activities of human
recombinant interleukin-2125 and native interleukin-2. J Biol
Response Mod 1985; 4:96-109.
2. Ralph P, Nakoinz I, Doyle M, et al. Human B and T lymphocyte stimulating
properties of interleukin-2 (IL-2) muteins. In: Immune Regulation By Characterized
Polypeptides. Alan R. Liss, Inc. 1987; 453-62.Last reviewed on RxList: 9/11/2008





Other reviews about Proleukin on wordpress

Aldesleukin
  by hijadoo
U.S. BRAND NAMES — Proleukin®PHARMACOLOGIC CATEGORY Biological Response ModulatorDOSING: ADULTS — Refer to individual protocols.Renal cell carcinoma: I.V.: 600,000 int. units/kg every 8 hours for a maximum of […]


Immuneering, Led by Young CEO and Mentor, Aims to Pick Which Cancer Drugs Should Work | Xconomy
  by biotechbeachbum
Boston-based Immuneering has pulled together the most concrete business case I've yet seen for the sort of Personalized Healthcare system we're trying to build with Healthcare IT plugged […]


Proleukin (Interleukin-2) Therapy for Renal Cell Carcinoma: Treatment Option for Select Patients
  by bmirtsching
Therapy options for patients with metastatic renal cell carcinoma has expanded significantly, with the FDA approval of sunitinib (Sutent), sorafenib (Nexavar), everolimus (Affinitor), temsirolimus (Torisel), and bevacizumab (Avastin).  These […]


Interleukin-2 Therapy in Patients with HIV Infection
  by JOC
N Engl J of Medicine  Oct 15, 2009  V.361  N.16  p.1548-1559 The INSIGHT–ESPRIT Study Group and SILCAAT Scientific Committee Background Used in combination with antiretroviral therapy, subcutaneous recombinant interleukin-2 […]


Prometheus Laboratories signs commercialization agreement with Novartis
  by silico
Prometheus Laboratories, a specialty pharmaceutical and diagnostic company, has signed a commercialization agreement with Novartis under which Prometheus acquired exclusive rights to distribute, promote and sell Proleukin in […]


World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition Reports
  by reportsnreports
Worldwide cancer affects more than 10 million people each year. This number is expected to increase by 2.4% by 2020 to 14 million each year. Worldwide approximately 22 […]


Taking a break-sort of
  by drkens
I will be away-one of my passions is photography. I am going on a photo expedition to the forests of Costa Rica. I will try and continue some […]


Will BioVex cure melanoma with its OncoVEX oncolytic virus?
  by Timo Ahopelto
Advanced melanoma for sure is a challenging enough target: there are no new FDA-approved medications since 20 years, 1-year survival in unresectable melanoma is at the level of […]


ReportsandReports – World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The
  by reportsnreports
Browse the complete Report on: World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Browse All Kalorama Information Reports at Kalorama Information Worldwide cancer affects more than 10 million […]


Those, Devine explained, are eith
  by uopglnkmdmthqw
I have myself been fortunate enough to encounter the bullroarer on the soil of ancient Greece and in connection with the Dionysiac mysteries. Alvina and Ciccio stood and […]



Other reviews about Proleukin on web:

Do you have metastatic melanoma? Learn if PROLEUKIN injection therapy is the right treatment for your kidney cancer or skin cancer. Metastatic Melanoma - Kidney Cancer - Skin Cancer - PROLEUKIN


Learn about the prescription medication Proleukin (Aldesleukin), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Proleukin (Aldesleukin) Drug Information: Uses, Side Effects, Drug ...


What is Proleukin Therapy and how does it work? Learn more about PROLEUKIN injection therapy as a melanoma and renal cell carcinoma treatment. PROLEUKIN | What is Proleukin Therapy?


All about Proleukin. View complete and up to date Proleukin information - part of the Drugs.com trusted medication database. Proleukin Facts and Comparisons at Drugs.com


Accurate, FDA approved Proleukin information for healthcare professionals and patients - brought to you by Drugs.com. Proleukin Official FDA information, side effects and uses.


A recombinant form of IL-2 for clinical use is manufactured by Chiron Corporation with the brand name Proleukin. It has been approved by the Food and Drug Administration (FDA) for ... Interleukin 2 - Wikipedia, the free encyclopedia


Complete info about Proleukin, an Immune-Based Therapy for HIV AIDSmeds.com - Proleukin


Proleukin is the trade name for the generic drug name Aldesleukin. Interleukin-2 and IL-2 are other names for Proleukin. Proleukin is a biologic response modifier classified as a ... Proleukin, Aldesleukin, Interleukin-2, IL-2 - Chemotherapy Drugs ...


What is Proleukin (Aldesleukin)? Aldesleukin is a cancer medication that interferes with tumor growth. Aldesleukin is used to treat kidney cancer or skin cancer than has spread to ... Proleukin - Drugs & Treatments - Revolution Health


PROLEUKIN® Aldesleukin For Injection Rx Only WARNINGS Therapy with PROLEUKIN ® (aldesleukin) for injection should be restricted to patients with normal cardiac and pulmonary functions ... DESCRIPTION





Featured Reviews

Reviews Mupirocin Calcium Ointment

Bactroban Nasal Drug Description BACTROBAN NASAL® (mupirocin calcium) Ointment, 2% for intranasal use only DRUG DESCRIPTION What are the possible side effects of mupirocin nasal (Bactroban)? Get emergency medical help if you...
Read More  |  Review This
Reviews Amino Acid

HepatAmine Drug Description HepatAmine® (8% Amino Acid) Injection Protect from light until use. DRUG DESCRIPTION HepatAmine (8% Amino Acid Injection) is a sterile, nonpyrogenic, hypertonic solution containing crystalline amino acids....
Read More  |  Review This
Reviews Fluoxetine Hcl

Prozac Drug Description PROZAC® (fluoxetine hydrochloride) Pulvule® for Oral Use PROZAC (fluoxetine hydrochloride) Oral Solution PROZAC Weekly™ (fluoxetine hydrochloride) Delayed-Release Capsules for Oral Use WARNING:...
Read More  |  Review This
Reviews Methylphenidate Hydrochloride Tablet

Metadate ER Drug Description METADATE ER (methylphenidate hydrochloride) Tablet Extended Release DRUG DESCRIPTION What are the possible side effects of methylphenidate? Get emergency medical help if you have any of these signs...
Read More  |  Review This
Reviews Cystagon

Cystagon Drug Description CYSTAGON® (cysteamine bitartrate capsules) 50 mg and 150 mg DRUG DESCRIPTION What are the possible side effects of cysteamine (Cystagon)? Get emergency medical help if your child has any of these signs...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....